Evidence map›Paper›PMID 39731298›Full record

ArticleThoracic cancer2025

Indocyanine Green Fluorescence Plus Blue Dye for Sentinel Lymph Node Biopsy in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer: A Multicenter, Prospective Cohort Study.

Miao Liu, Yang Yang, Bin Hua, Rui Feng, Tianyu Xu, Mengyuan Wang, Xiaowei Qi, Yingming Cao, Bo Zhou, Fuzhong Tong and 12 more

Registry-linked trialAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02869815 (Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy Using the Navigation of the Combination of Indocyanine and Blue Dye in Patients With Breast Cancer), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02869815 unknown statusnot on this map

Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy Using the Navigation of the Combination of Indocyanine and Blue Dye in Patients With Breast Cancer

TypeobservationalSponsorPeking University People's HospitalRan2016 to 2020Enrolled150ConditionsBreast NeoplasmsArmsICG+Methylene Blue
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Ethnic disparities in survival and progression among EGFR-mutated adenocarcinoma of lung cancer patients treated with tyrosine kinase inhibitors: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Miao LiuBreast Disease Center, Peking University People's Hospital, Beijing, China.
Yang YangBreast Disease Center, Peking University People's Hospital, Beijing, China.
Bin HuaDepartment of General Surgery, Beijing Hospital, Beijing, China.
Rui FengDepartment of Breast Surgery, Tianjin Central Hospital of Obstetrics and Gynecology, Tian Jin, China.
Tianyu XuBreast Disease Center, Peking University People's Hospital, Beijing, China.
Mengyuan WangDepartment of Breast Surgery, Chongqing University Three Gorges Hospital, Chong Qing, China.
Xiaowei QiDepartment of Breast Surgery, Southwest Hospital, Chong Qing, China.
Yingming CaoBreast Disease Center, Peking University People's Hospital, Beijing, China.
Bo ZhouBreast Disease Center, Peking University People's Hospital, Beijing, China.
Fuzhong TongBreast Disease Center, Peking University People's Hospital, Beijing, China.
Peng LiuBreast Disease Center, Peking University People's Hospital, Beijing, China.
Hongjun LiuBreast Disease Center, Peking University People's Hospital, Beijing, China.
Lin ChengBreast Disease Center, Peking University People's Hospital, Beijing, China.
Houpu YangBreast Disease Center, Peking University People's Hospital, Beijing, China.
Fei XieBreast Disease Center, Peking University People's Hospital, Beijing, China.
Siyuan WangBreast Disease Center, Peking University People's Hospital, Beijing, China.
Chaobin WangBreast Disease Center, Peking University People's Hospital, Beijing, China.
Yuan PengBreast Disease Center, Peking University People's Hospital, Beijing, China.
Danhua ShenDepartment of Pathology, Peking University People's Hospital, Beijing, China.
Lei ChenDepartment of Radiology, Peking University People's Hospital, Beijing, China.
Jun JiangDepartment of Breast Surgery, Southwest Hospital, Chong Qing, China.
Shu WangBreast Disease Center, Peking University People's Hospital, Beijing, China.ORCID https://orcid.org/0000-0002-8651-4795

Funding

Capital Health Research and Development of Special Fund 2014-2-4083Capital Health Research and Development of Special Fund 2020-2Z-40812National Natural Science Foundation of China 92059105
6 · The paper itself

Abstract

backgroundSentinel lymph node biopsy (SLNB) using radioisotope tracer plus blue dye is the gold standard after neoadjuvant chemotherapy (NAC) in initially cN1 breast cancer patients, but clinical use still has limitations. This study aims to examine diagnostic performance of dual indocyanine green (ICG) and methylene blue tracing for SLNB in patients who have completed NAC for breast cancer with initially cN1 disease.

methodsAdult women (20-80 years of age) scheduled to undergo NAC for biopsy-proven cT0-3N1M0 primary invasive breast cancer were consecutively enrolled in this prospective, multicenter, cohort study. Upon the completion of NAC, SLNB was conducted using ICG and methylene blue, followed by axillary lymph node dissection. The primary outcome was the detection rate (DR); secondary outcomes included the false-negative rate (FNR) and adverse events associated with the use of tracers.

resultsA total of 156 patients were enrolled; all underwent SLNB after NAC. The median number of lymph nodes retrieved during SLNB was 3 (range: 0-11). The DR was 97.4% (152/156; 95% CI, 93.6%-99.0%). The FNR was 6.7% (4/60; 95% CI, 2.6%-15.9%). Negative predictive value was 95.7% (88/92; 95% CI, 89.4%-98.3%). In the subgroup analysis stratified by ycN status, FNR was 4.0% (1/25; 95% CI, 0.7%-19.5%) and 8.6% (3/35; 95% CI, 3.0%-22.4%) in the ycN0 and ycN+ subgroups, respectively. No allergic reaction was reported.

conclusionsSLNB with ICG plus methylene blue achieved a high DR and a very low FNR in breast cancer patients with initially cN1 disease.

trial registrationClinicalTrials.gov (https://www. CLINICALTRIALS: gov/), NCT02869815.

Indexed as

Breast NeoplasmsIndocyanine GreenMethylene BlueNeoadjuvant TherapySentinel Lymph Node BiopsyAdultAgedAged, 80 and overFemaleHumansMiddle AgedProspective StudiesYoung AdultIndocyanine GreenMethylene Bluebreast cancerindocyanine green fluorescenceneoadjuvant chemotherapysentinel lymph node biopsy

Identifiers

PMID39731298
PMCPMC11735736

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.